1479 related articles for article (PubMed ID: 32223444)
61. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
[TBL] [Abstract][Full Text] [Related]
62. Antithrombotic Therapy With or Without Aspirin After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients Taking Oral Anticoagulation: A Meta-Analysis and Network Analysis of Randomized Controlled Trials.
Colleran R; Byrne RA; Ndrepepa G; Alvarez-Covarrubias HA; Mayer K; Kuna C; Rai H; Kastrati A; Cassese S
Cardiovasc Revasc Med; 2022 Mar; 36():99-106. PubMed ID: 34099410
[TBL] [Abstract][Full Text] [Related]
63. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study.
Reinecke H; Engelbertz C; Bauersachs R; Breithardt G; Echterhoff HH; Gerß J; Haeusler KG; Hewing B; Hoyer J; Juergensmeyer S; Klingenheben T; Knapp G; Christian Rump L; Schmidt-Guertler H; Wanner C; Kirchhof P; Goerlich D
Circulation; 2023 Jan; 147(4):296-309. PubMed ID: 36335915
[TBL] [Abstract][Full Text] [Related]
64. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
Berry NC; Mauri L; Steg PG; Bhatt DL; Hohnloser SH; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Ten Berg JM; Cannon CP
Circ Cardiovasc Interv; 2020 Apr; 13(4):e008349. PubMed ID: 32252548
[TBL] [Abstract][Full Text] [Related]
65. Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort.
Said A; Keeney S; Matka M; Hafeez A; George J; Halalau A
BMC Cardiovasc Disord; 2020 Jun; 20(1):263. PubMed ID: 32487114
[TBL] [Abstract][Full Text] [Related]
66. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
67. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
Kopin D; Jones WS; Sherwood MW; Wojdyla DM; Wallentin L; Lewis BS; Verheugt FWA; Vinereanu D; Bahit MC; Halvorsen S; Huber K; Parkhomenko A; Granger CB; Lopes RD; Alexander JH
Am Heart J; 2018 Mar; 197():133-141. PubMed ID: 29447773
[TBL] [Abstract][Full Text] [Related]
68. Meta-analysis of Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
Kuno T; Ueyama H; Takagi H; Ando T; Numasawa Y; Briasoulis A; Fox J; Bangalore S
Am J Cardiol; 2020 Feb; 125(4):521-527. PubMed ID: 31839147
[TBL] [Abstract][Full Text] [Related]
69. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
[TBL] [Abstract][Full Text] [Related]
70. Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression.
Osawa K; Nakanishi R; Win TT; Li D; Rahmani S; Nezarat N; Sheidaee N; Budoff MJ
Clin Cardiol; 2017 Oct; 40(10):807-813. PubMed ID: 28703931
[TBL] [Abstract][Full Text] [Related]
71. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
[TBL] [Abstract][Full Text] [Related]
72. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
[TBL] [Abstract][Full Text] [Related]
73. New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint.
Rubboli A; Agewall S; Huber K; Lip GY
Int J Cardiol; 2015 Oct; 196():133-8. PubMed ID: 26093527
[TBL] [Abstract][Full Text] [Related]
74. Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial.
Vranckx P; Valgimigli M; Eckardt L; Lewalter T; Unikas R; Marin F; Schiele F; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Tijssen J; Goette A
Eur Heart J; 2020 Dec; 41(47):4497-4504. PubMed ID: 32860041
[TBL] [Abstract][Full Text] [Related]
75. Safety and Efficacy of Oral Anticoagulants Therapies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-Analysis.
Mainka FF; Ferreira VL; Mendes AM; Marques GL; Fernandez-Llimos F; Tonin FS; Pontarolo R
J Cardiovasc Pharmacol Ther; 2020 Sep; 25(5):399-408. PubMed ID: 32489116
[TBL] [Abstract][Full Text] [Related]
76. Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
Thompson PL; Verheugt FW
Clin Ther; 2014 Sep; 36(9):1176-81. PubMed ID: 25234549
[TBL] [Abstract][Full Text] [Related]
77. Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events.
Cordero A; Ferreiro JL; Bertomeu-González V; Rodríguez-Mañero M; Fácila L; Escribano D; Sanchez-Recalde A; Zuazola P; Ruiz-Nodar JM; González-Juanatey JR
J Cardiovasc Pharmacol; 2021 Feb; 77(2):164-169. PubMed ID: 33351537
[TBL] [Abstract][Full Text] [Related]
78. Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect.
Guimarães PO; Lopes RD; Wojdyla DM; Abdul-Rahim AH; Connolly SJ; Flaker GC; Wang J; Hanna M; Granger CB; Wallentin L; Lees KR; Alexander JH; McMurray JJV
Cardiovasc Drugs Ther; 2017 Jun; 31(3):295-301. PubMed ID: 28516318
[TBL] [Abstract][Full Text] [Related]
79. Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy?
Fluschnik N; Becher PM; Schnabel R; Blankenberg S; Westermann D
Herz; 2018 Feb; 43(1):20-25. PubMed ID: 29188358
[TBL] [Abstract][Full Text] [Related]
80. In AF with recent ACS or PCI, apixaban improved 30-day outcomes vs. VKAs; aspirin effects varied vs. placebo.
Hoffer EP
Ann Intern Med; 2020 Sep; 173(6):JC29. PubMed ID: 32926823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
